ADVA
9.12.2021 09:20:09 CET | Business Wire | Press release
ADVA (FSE: ADV) today announced the latest software release of its core and edge timing technology, bringing new levels of PNT security and resilience to synchronization networks. The upgraded series of PTP grandmaster clock solutions now enables operators to automatically harness public key infrastructure. Along with enhanced certificate management, this delivers more robust security and removes complexity. ADVA’s core and mid-sized PTP grandmaster devices now also integrate enhanced aPNT+™ technology , providing advanced jamming and spoofing detection as well as mitigation with automatic switchover in the event of cyberattacks. The software replaces costly hardware devices previously used for PNT protection and achieves enhanced DHS Level 4 Resiliency in PNT self-survivability, the highest in the industry. What’s more, the new software release supports 100Mbit/s over fiber for interconnectivity with optical timing channels from third-part vendors as well as support for PTP profiles for a wide range of industries.
“Today’s timing networks require greater accuracy than ever before. But mission-critical national networks need improved resilience and security as defined by the latest standards. With our trusted PNT assurance solutions, we’re providing the GNSS protection and cybersecurity that today’s operators need to meet current and future challenges,” said Gil Biran, GM of Oscilloquartz, ADVA. “From phase synchronization in critical national infrastructure to traceable timestamping in financial networks, highly precise and protected timing is key to successful operations. This upgrade sets a new standard for secure synchronization and delivers it to more networks than ever before.”
The new 11.1.1 software release features upgrades to ADVA’s comprehensive range of Oscilloquartz edge timing products, the OSA 5412/22 Series, as well as its core synchronization devices, the OSA 5430/40 Series. The solutions now provide multi-layered security for synchronization infrastructure through improved certification management and PKI. As part of ADVA’s intelligent and scalable assured PNT platform, the ADVA aPNT+™ , the solutions also feature innovation for detection of spoofing and jamming as well as countermeasures to prevent service disruption. With PTP capabilities for new verticals, including the PTP broadcast profiles (SMPTE ST-2059-2/AES67), the new release will bring precise, reliable synchronization to many new customers.
The new release follows the four layers of augmented protection as defined in the DHS Resilient PNT Conformance Framework (IEEE P1952 Resilient PNT UE working group). These are: antenna level with a new anti-jamming antenna; GNSS receiver level with single and multi-band options; device level with state-of-the-art anti-jamming and spoofing technology; and network level with sophisticated anti-jamming and anti-spoofing technology based on our Ensemble Controller with Sync Director management suite. Additionally, the device and network levels integrate multi-source backup for diversity and multi-level fault-tolerant mitigation for trusted PNT assurance protection, prevention and recovery.
“In a lot of industries and government networks, failure of network synchronization is no longer an option. It could have devastating consequences for a business’s future or even put lives at risk. That’s why more and more customers are deploying our portfolio of the most advanced and comprehensive aPNT+™ timing technology. As well as ensuring nanosecond accuracy, our enhanced series of PTP grandmasters now provide the most robust defense against cyberattacks,” commented Nir Laufer, VP of product line management at Oscilloquartz, ADVA. “This release extends many of our most powerful features beyond telecom. It opens the door for government, defense, broadcasters, data centers, smart grids and more to take advantage of technologies like our multi-band receivers and AI-power GNSS protection.”
Further information is available in these slides: https://adva.li/apnt-security-enhancements-slides .
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com
.
About Oscilloquartz
Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we’re creating new opportunities for tomorrow’s networks. For more information, please visit us at www.oscilloquartz.com
.
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20211209005047/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
